MedTrace Logo

Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

NCT04038710 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2021-03-11

No results posted yet for this study

Summary

This is an observational study of people with severe cystic fibrosis that are eligible for Vertex's triple combination therapy through its expanded access. Pulmonary health, intestinal health, and the overall health of individuals will be tracked for a year to see how effective triple combination therapy is in these people with severe cystic fibrosis disease.

Conditions

Interventions

DRUG

Triple combination therapy

Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.

Sponsors & Collaborators

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Derek Low, MD · National Jewish Health

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2021-02-26
Completion
2021-02-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04038710 on ClinicalTrials.gov